SEC Company Response from ACORDA THERAPEUTICS INC (CIK 0001008848) — Jan 22, 2020

ACORDA THERAPEUTICS INC (CIK 0001008848)
Date: Jan. 22, 2020 · CIK: 0001008848 · Accession: 0001564590-20-001636

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-235929

Date

January 22, 2020

Author

By: /s/ Andrew Mayer

Form

CORRESP

Company

ACORDA THERAPEUTICS INC (CIK 0001008848)

Letter

Re: Acorda Therapeutics, Inc. Registration Statement on Form S-3 Filed January 15, 2020 File No. 333-235929

acor-corresp.htm

ACORDA THERAPEUTICS, INC.

420 SAW MILL RIVER ROAD

ARDSLEY, NY 10502

January 22, 2020

VIA EDGAR

U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, Acorda Therapeutics, Inc. hereby requests that the effective date for above-referenced Registration Statement on Form S-3 be accelerated to 4:00 p.m., Eastern Time, on Friday, January 24, 2020, or as soon as practicable thereafter.

Please contact Matthew C. Franker of Covington & Burling LLP at (202) 662-5895 or mfranker@cov.com with any questions you may have regarding this request. In addition, please notify Mr. Franker when this request for acceleration has been granted.

Respectfully,
Acorda Therapeutics, Inc.

Show Raw Text

CORRESP
1
filename1.htm

acor-corresp.htm

ACORDA THERAPEUTICS, INC.

420 SAW MILL RIVER ROAD

ARDSLEY, NY  10502

January 22, 2020

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tim Buchmiller

Re:       Acorda Therapeutics, Inc.
Registration Statement on Form S-3
Filed January 15, 2020
File No. 333-235929

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, Acorda Therapeutics, Inc. hereby requests that the effective date for above-referenced Registration Statement on Form S-3 be accelerated to 4:00 p.m., Eastern Time, on Friday, January 24, 2020, or as soon as practicable thereafter.

Please contact Matthew C. Franker of Covington & Burling LLP at (202) 662-5895 or mfranker@cov.com with any questions you may have regarding this request. In addition, please notify Mr. Franker when this request for acceleration has been granted.

Respectfully,

Acorda Therapeutics, Inc.

By: /s/ Andrew Mayer
Name:   Andrew Mayer
Title:     Senior Vice President,

              Deputy General Counsel and

              Corporate Secretary

cc:  Matthew C. Franker
       Covington & Burling LLP

SecProbe.io